Skip to main content

Table 2 Effect of empagliflozin on morphometric parameters of different organs and body weight in the lean control and ZSF1 groups

From: Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

 ControlEmpaZSF1ZSF1 + Empa
Spleen (mg mm−1)17.45 ± 0.3816.55 ± 0.6220.90 ± 0.32*18.53 ± 0.81#
Liver (mg mm−1)286.40 ± 12.58264.80 ± 7.80771.40 ± 34.64*547.90 ± 21.37*,#
Kidney (mg mm−1)40.52 ± 1.3341.58 ± 1.3455.22 ± 1.46*54.92 ± 1.60*
Perirenal fat (mg mm−1)11.32 ± 1.858.47 ± 1.63183.70 ± 36.89*100.60 ± 27.25*,#
Left lung (mg mm−1)11.06 ± 0.2010.65 ± 0.6512.92 ± 0.69*11.02 ± 0.25#
Dry weight of left lung (mg mm−1)2.30 ± 0.032.16 ± 0.062.70 ± 0.08*2.42 ± 0.06#
3 lobes of lung (mg mm−1)17.94 ± 0.4116.40 ± 0.4121.48 ± 1.64*17.23 ± 0.37#
Heart (mg mm−1)31.93 ± 0.6628.74 ± 0.75*38.98 ± 0.95*35.40 ± 0.63*,#
Tibial length (mm)41.76 ± 0.3542.54 ± 0.5340.22 ± 0.4239.89 ± 0.43
Weight (g)407.70 ± 9.07366.00 ± 7.67*523.80 ± 19.93*478.90 ± 8.73*,#
  1. Organs were weighted and indexed to the respective tibial length. Values are shown as mean ± SEM of n = 7–10 per group
  2. Empa empagliflozin
  3. * P < 0.05 vs control group and #P < 0.05 vs ZSF1 group